HLS Therapeutics Inc(DE:74D)
€2.54-0.12 (-5.93%)
DE:74D
HLS Therapeutics Inc financials statements
€2.54
At close:-0.12 (-5.93%)
HLS Therapeutics Inc (74D) Ratios
0 Followers
HLS Therapeutics Inc Ratios
DE:74D's free cash flow for Q2 2026 was $2.84M. For the 2026 fiscal year, DE:74D's free cash flow was increased by $0.00 and operating cash flow was $2.84M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.11 | 1.57 | 1.65 | 1.42 | 1.58 |
| Quick Ratio | 0.80 | 1.17 | 1.30 | 1.14 | 1.26 |
| Cash Ratio | 0.45 | 0.77 | 0.82 | 0.66 | 0.77 |
| Solvency Ratio | 0.13 | 0.03 | 0.04 | 0.09 | 0.15 |
| Operating Cash Flow Ratio | 0.61 | 0.35 | 0.59 | 0.54 | 0.59 |
| Short-Term Operating Cash Flow Coverage | 3.70 | 1.66 | 3.37 | 1.30 | 1.37 |
| Net Current Asset Value | $ -46.68M | $ -53.16M | $ -67.27M | $ -71.96M | $ -71.42M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.36 | 0.42 | 0.42 | 0.40 | 0.35 |
| Debt-to-Equity Ratio | 0.81 | 0.93 | 0.90 | 0.78 | 0.61 |
| Debt-to-Capital Ratio | 0.45 | 0.48 | 0.47 | 0.44 | 0.38 |
| Long-Term Debt-to-Capital Ratio | 0.42 | 0.46 | 0.46 | 0.40 | 0.34 |
| Financial Leverage Ratio | 2.23 | 2.24 | 2.14 | 1.93 | 1.72 |
| Debt Service Coverage Ratio | 1.60 | 0.88 | 0.98 | 0.89 | 1.27 |
| Interest Coverage Ratio | -0.58 | -0.76 | -1.18 | -1.84 | -0.90 |
| Debt to Market Cap | 0.44 | 0.75 | 0.90 | 0.41 | 0.25 |
| Interest Debt Per Share | 1.81 | 2.40 | 2.99 | 3.24 | 3.25 |
| Net Debt to EBITDA | 2.11 | 2.85 | 5.10 | 4.26 | 3.01 |
| Profitability Margins | |||||
| Gross Profit Margin | 42.52% | 84.11% | 87.91% | 91.90% | 93.38% |
| EBIT Margin | -7.40% | -9.71% | -30.21% | -26.69% | -8.09% |
| EBITDA Margin | 31.91% | 30.41% | 20.43% | 29.28% | 42.35% |
| Operating Profit Margin | -7.40% | -13.57% | -16.41% | -21.87% | -10.40% |
| Pretax Profit Margin | -23.20% | -27.52% | -44.08% | -38.59% | -19.68% |
| Net Profit Margin | -22.40% | -34.71% | -43.65% | -38.39% | -21.86% |
| Continuous Operations Profit Margin | -22.40% | -34.71% | -43.65% | -38.39% | -21.86% |
| Net Income Per EBT | 96.54% | 126.14% | 99.02% | 99.48% | 111.09% |
| EBT Per EBIT | 313.57% | 202.73% | 268.65% | 176.50% | 189.23% |
| Return on Assets (ROA) | -9.21% | -12.29% | -13.17% | -9.77% | -4.75% |
| Return on Equity (ROE) | -20.55% | -27.55% | -28.18% | -18.83% | -8.16% |
| Return on Capital Employed (ROCE) | -3.76% | -5.60% | -5.67% | -6.39% | -2.51% |
| Return on Invested Capital (ROIC) | -3.48% | -5.39% | -5.46% | -5.97% | -2.39% |
| Return on Tangible Assets | -39.72% | -52.02% | -58.93% | -50.60% | -28.07% |
| Earnings Yield | -11.43% | -22.60% | -28.65% | -10.07% | -3.44% |
| Efficiency Ratios | |||||
| Receivables Turnover | 7.20 | 7.52 | 5.90 | 5.49 | 5.21 |
| Payables Turnover | 3.12 | 1.03 | 0.54 | 0.43 | 0.43 |
| Inventory Turnover | 4.00 | 0.99 | 0.80 | 0.56 | 0.45 |
| Fixed Asset Turnover | 42.28 | 56.79 | 65.36 | 54.54 | 38.25 |
| Asset Turnover | 0.41 | 0.35 | 0.30 | 0.25 | 0.22 |
| Working Capital Turnover Ratio | 7.14 | 3.74 | 4.12 | 4.20 | 4.56 |
| Cash Conversion Cycle | 24.92 | 62.67 | -157.05 | -130.57 | 34.08 |
| Days of Sales Outstanding | 50.72 | 48.51 | 61.88 | 66.47 | 70.01 |
| Days of Inventory Outstanding | 91.36 | 367.47 | 456.44 | 652.32 | 820.15 |
| Days of Payables Outstanding | 117.16 | 353.32 | 675.37 | 849.37 | 856.08 |
| Operating Cycle | 142.08 | 415.99 | 518.33 | 718.80 | 890.16 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 0.51 | 0.25 | 0.49 | 0.52 | 0.51 |
| Free Cash Flow Per Share | 0.50 | 0.25 | 0.48 | 0.21 | 0.37 |
| Dividend Paid and CapEx Coverage Ratio | 76.79 | 533.53 | 6.10 | 1.12 | 1.71 |
| Capital Expenditure Coverage Ratio | 76.79 | 533.53 | 83.54 | 1.67 | 3.64 |
| Operating Cash Flow Coverage Ratio | 0.32 | 0.12 | 0.18 | 0.17 | 0.17 |
| Operating Cash Flow to Sales Ratio | 0.28 | 0.14 | 0.25 | 0.28 | 0.27 |
| Free Cash Flow Yield | 14.29% | 9.19% | 16.24% | 2.90% | 3.12% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -8.77 | -4.40 | -3.49 | -9.93 | -29.10 |
| Price-to-Sales (P/S) Ratio | 1.96 | 1.54 | 1.52 | 3.81 | 6.36 |
| Price-to-Book (P/B) Ratio | 1.80 | 1.22 | 0.98 | 1.87 | 2.37 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 7.00 | 10.89 | 6.16 | 34.50 | 32.02 |
| Price-to-Operating Cash Flow Ratio | 6.91 | 10.86 | 6.09 | 13.84 | 23.23 |
| Price-to-Earnings Growth (PEG) Ratio | 0.25 | 0.16 | -0.21 | -0.13 | 2.00 |
| Enterprise Value Multiple | 8.25 | 7.90 | 12.55 | 17.28 | 18.03 |
| Enterprise Value | 148.68M | 135.95M | 161.75M | 311.04M | 458.06M |
| EV to EBITDA | 8.25 | 7.90 | 12.55 | 17.28 | 18.03 |
| EV to Sales | 2.63 | 2.40 | 2.56 | 5.06 | 7.63 |
| EV to Free Cash Flow | 9.41 | 17.02 | 10.37 | 45.78 | 38.43 |
| EV to Operating Cash Flow | 9.28 | 16.99 | 10.24 | 18.36 | 27.88 |
| Tangible Book Value Per Share | -1.39 | -1.59 | -2.00 | -2.16 | -2.13 |
| Shareholders’ Equity Per Share | 1.95 | 2.24 | 3.03 | 3.88 | 4.99 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.03 | -0.26 | 0.01 | 0.01 | -0.11 |
| Revenue Per Share | 1.79 | 1.78 | 1.95 | 1.90 | 1.86 |
| Net Income Per Share | -0.40 | -0.62 | -0.85 | -0.73 | -0.41 |
| Tax Burden | 0.97 | 1.26 | 0.99 | 0.99 | 1.11 |
| Interest Burden | 3.14 | 2.83 | 1.46 | 1.45 | 2.43 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.39 | 0.48 | 0.13 | 0.29 | 0.29 |
| Stock-Based Compensation to Revenue | 0.03 | 0.03 | -0.01 | 0.05 | 0.04 |
| Income Quality | -1.29 | -0.41 | -0.57 | -0.72 | -1.25 |
Currency in USD
